GENERALI, DANIELE
 Distribuzione geografica
Continente #
NA - Nord America 5.438
AS - Asia 2.609
EU - Europa 2.579
AF - Africa 100
OC - Oceania 62
SA - Sud America 62
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.851
Nazione #
US - Stati Uniti d'America 5.323
CN - Cina 1.770
IT - Italia 1.251
DE - Germania 310
FR - Francia 238
GB - Regno Unito 152
IN - India 140
VN - Vietnam 126
JP - Giappone 115
CA - Canada 97
HK - Hong Kong 93
PL - Polonia 84
NL - Olanda 71
KR - Corea 68
IE - Irlanda 62
AU - Australia 59
TW - Taiwan 57
ES - Italia 55
FI - Finlandia 52
UA - Ucraina 42
ZA - Sudafrica 38
SG - Singapore 34
CZ - Repubblica Ceca 32
EG - Egitto 30
RU - Federazione Russa 30
TR - Turchia 28
AT - Austria 27
IR - Iran 27
ID - Indonesia 26
BR - Brasile 25
CL - Cile 25
RO - Romania 20
CH - Svizzera 17
DK - Danimarca 17
MO - Macao, regione amministrativa speciale della Cina 17
TH - Thailandia 17
GR - Grecia 16
SE - Svezia 16
BE - Belgio 15
MK - Macedonia 15
PT - Portogallo 14
AE - Emirati Arabi Uniti 13
MX - Messico 13
PH - Filippine 13
IQ - Iraq 12
PK - Pakistan 12
SA - Arabia Saudita 12
HU - Ungheria 6
IL - Israele 6
LT - Lituania 6
BG - Bulgaria 5
CO - Colombia 5
MA - Marocco 5
MY - Malesia 5
NG - Nigeria 5
NO - Norvegia 5
SI - Slovenia 5
TN - Tunisia 4
UG - Uganda 4
AL - Albania 3
CY - Cipro 3
EC - Ecuador 3
EE - Estonia 3
NZ - Nuova Zelanda 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
AR - Argentina 2
BD - Bangladesh 2
BJ - Benin 2
GH - Ghana 2
HR - Croazia 2
JO - Giordania 2
KE - Kenya 2
PE - Perù 2
QA - Qatar 2
SD - Sudan 2
YE - Yemen 2
A1 - Anonimo 1
AZ - Azerbaigian 1
BH - Bahrain 1
BZ - Belize 1
CI - Costa d'Avorio 1
CU - Cuba 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
ME - Montenegro 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
Totale 10.851
Città #
Fairfield 672
Ashburn 542
Beijing 517
Trieste 495
Houston 381
Seattle 339
Woodbridge 332
Buffalo 280
Santa Cruz 230
Cambridge 214
Wilmington 207
Columbus 170
Shanghai 157
Ann Arbor 153
Dong Ket 108
Wuhan 103
Milan 88
Chicago 84
Guangzhou 82
Rome 82
Nanjing 81
Warsaw 66
Dublin 59
Los Angeles 57
Hangzhou 51
Boardman 45
Las Vegas 43
Paris 42
Mountain View 38
Chengdu 37
Phoenix 34
Muizenberg 32
San Diego 32
Taipei 32
Jinan 31
Lappeenranta 29
New York 29
San Jose 29
University Park 29
Bengaluru 28
Naples 28
Changchun 27
Hefei 27
Ottawa 27
Amsterdam 25
Clearwater 24
Council Bluffs 24
Frankfurt am Main 24
Henderson 24
Shenyang 23
Tokyo 23
Dallas 22
Des Moines 22
Helsinki 22
London 22
Seoul 22
Barcelona 21
San Francisco 21
Toronto 20
Nürnberg 19
Singapore 19
Central 18
Lake Forest 18
Central District 17
Florence 17
Riva 17
Changsha 16
Chongqing 15
Fremont 15
Udine 15
Zhengzhou 15
Irvine 14
Monfalcone 14
Delhi 13
Jakarta 13
Norwalk 13
Sydney 13
Melbourne 12
Milpitas 12
Chennai 11
Fuzhou 11
Hanoi 11
Herndon 11
Huntingdon Valley 11
Lanzhou 11
Redmond 11
Turin 11
Wenzhou 11
Brescia 10
Dongguan 10
Hong Kong 10
Hyderabad 10
Leawood 10
Macao 10
Nanchang 10
Philadelphia 10
Suzhou 10
Vienna 10
Yellow Springs 10
Athens 9
Totale 7.031
Nome #
Apatinib for the treatment of gastric cancer, file e2913fdb-5966-f688-e053-3705fe0a67e0 1.220
Current challenges in HER2-positive breast cancer, file e2913fdb-58d9-f688-e053-3705fe0a67e0 676
Lenvatinib for the treatment of renal cell carcinoma, file e2913fdd-82b6-f688-e053-3705fe0a67e0 515
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper, file e2913fdc-d489-f688-e053-3705fe0a67e0 358
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy, file e2913fde-36ac-f688-e053-3705fe0a67e0 352
Abemaciclib: A CDK4/6 inhibitor for the treatment of HR+/HEeR2- advanced breast cancer, file e2913fdc-d0a0-f688-e053-3705fe0a67e0 337
Broad targeting of angiogenesis for cancer prevention and therapy, file e2913fdb-5a81-f688-e053-3705fe0a67e0 310
Designing a broad-spectrum integrative approach for cancer prevention and treatment, file e2913fdb-6864-f688-e053-3705fe0a67e0 236
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?, file e2913fdc-3bf3-f688-e053-3705fe0a67e0 221
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene, file e2913fdc-d40a-f688-e053-3705fe0a67e0 219
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma, file e2913fdb-9a7c-f688-e053-3705fe0a67e0 216
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer, file e2913fdc-615d-f688-e053-3705fe0a67e0 213
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit, file e2913fdc-d416-f688-e053-3705fe0a67e0 200
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility, file e2913fdb-5f2b-f688-e053-3705fe0a67e0 196
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study., file e2913fdc-6eb3-f688-e053-3705fe0a67e0 189
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer, file e2913fdc-d259-f688-e053-3705fe0a67e0 181
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma, file e2913fdb-5c57-f688-e053-3705fe0a67e0 177
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma, file e2913fdc-f266-f688-e053-3705fe0a67e0 172
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial, file e2913fdb-6a56-f688-e053-3705fe0a67e0 166
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer, file e2913fdb-fe1c-f688-e053-3705fe0a67e0 166
Bevacizumab in small cell lung cancer, file e2913fdc-053f-f688-e053-3705fe0a67e0 164
Isolated testicular metastasis from prostate cancer, file e2913fdb-fe0d-f688-e053-3705fe0a67e0 160
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer, file e2913fda-0578-f688-e053-3705fe0a67e0 158
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study, file e2913fdb-71a4-f688-e053-3705fe0a67e0 158
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts, file e2913fdc-d25d-f688-e053-3705fe0a67e0 157
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer, file e2913fdc-05b5-f688-e053-3705fe0a67e0 153
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells, file e2913fdc-d0a7-f688-e053-3705fe0a67e0 145
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study, file e2913fdc-a29f-f688-e053-3705fe0a67e0 133
Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?, file e2913fdb-6f42-f688-e053-3705fe0a67e0 124
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition, file e2913fdb-6636-f688-e053-3705fe0a67e0 120
Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis, file e2913fdb-5fdc-f688-e053-3705fe0a67e0 118
Characterization of MTAP gene expression in breast cancer patients and cell lines, file e2913fdb-61f2-f688-e053-3705fe0a67e0 118
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration, file e2913fdb-5c18-f688-e053-3705fe0a67e0 111
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies, file e2913fdc-2c15-f688-e053-3705fe0a67e0 110
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy, file e2913fdc-181e-f688-e053-3705fe0a67e0 105
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials, file e2913fdf-155a-f688-e053-3705fe0a67e0 103
Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes, file e2913fda-008e-f688-e053-3705fe0a67e0 99
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study, file e2913fdc-b384-f688-e053-3705fe0a67e0 97
BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?, file e2913fdf-76bc-f688-e053-3705fe0a67e0 90
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature, file e2913fde-2543-f688-e053-3705fe0a67e0 88
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study, file e2913fde-8323-f688-e053-3705fe0a67e0 81
Early changes of the standardized uptake values (SUVmax) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer, file e2913fde-36a9-f688-e053-3705fe0a67e0 70
Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer, file e2913fde-7f5a-f688-e053-3705fe0a67e0 69
Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers, file e2913fdf-01ac-f688-e053-3705fe0a67e0 59
Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS, file e2913fdf-bbba-f688-e053-3705fe0a67e0 59
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma, file e2913fdb-d791-f688-e053-3705fe0a67e0 58
P53 antibodies as a diagnostic marker for cancer: A meta-analysis, file e2913fdf-76bf-f688-e053-3705fe0a67e0 53
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis, file e2913fdc-2c19-f688-e053-3705fe0a67e0 50
Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste, file e2913fdf-1dd8-f688-e053-3705fe0a67e0 49
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report, file 82df134a-3361-45aa-a354-1b1e0bde9d6d 44
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer, file e2913fdb-95f1-f688-e053-3705fe0a67e0 42
Impact of psychosocial, behavioral and lifestyle factors on subjective cognitive complaints and perceived quality of life in a large cohort of Italian breast cancer patients, file 1cdbdab8-66cf-4e34-86d8-9ae5392fe8fe 41
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-Positive breast cancer patients treated with chemotherapy and HER2-Targeted agents in the CherLOB trial, file e2913fdf-457b-f688-e053-3705fe0a67e0 38
A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection, file 2709e941-8cc1-40fd-9924-a3e3be84594b 36
Treating advanced breast cancer with metronomic chemotherapy: What is known, what is new and what is the future?, file a03bea5c-644b-451a-ab12-a1b18a5bfac7 36
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study, file d4c97161-fb64-4738-a23a-9fd9bc7b5496 36
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial, file e2913fde-36a7-f688-e053-3705fe0a67e0 36
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score, file e2913fde-c11d-f688-e053-3705fe0a67e0 36
The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets, file 74eb81ad-b44e-442d-a9c3-0123e5b39733 34
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy, file e2913fde-bc16-f688-e053-3705fe0a67e0 34
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials, file e2913fdb-5fde-f688-e053-3705fe0a67e0 33
Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer, file e2913fdd-5095-f688-e053-3705fe0a67e0 32
Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications, file 9592e9f4-848c-4d83-b144-3c7325a9846c 31
Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study, file e2913fde-3c14-f688-e053-3705fe0a67e0 28
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis, file e2913fde-7b47-f688-e053-3705fe0a67e0 28
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET), file e2913fdf-155b-f688-e053-3705fe0a67e0 28
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation, file b5314b26-6389-4e00-8cce-f0c8e4b2df24 27
Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer, file e2913fde-4d58-f688-e053-3705fe0a67e0 26
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer, file 37828fe0-15d8-498f-be8e-99dde4d17714 24
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation, file 5edc65f5-24f7-480b-850a-b89025e610b5 24
Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS, file e2913fdf-bda0-f688-e053-3705fe0a67e0 24
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial, file e2913fde-4d52-f688-e053-3705fe0a67e0 23
Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer, file 46250e37-ab51-4473-a084-f1b0607fe7d0 22
Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses, file cab21b97-0562-49e6-98ff-ed44a739ea5e 22
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer, file e2913fdf-76c4-f688-e053-3705fe0a67e0 22
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration, file e2913fdb-7e29-f688-e053-3705fe0a67e0 21
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice, file ae451a81-378a-48a9-8701-fcb6b333a0ee 20
Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair, file c17be2fd-de8c-4a6c-bfb4-c7d0a69b59eb 20
Mutant p53 as an antigen in cancer immunotherapy, file e2913fde-7f5c-f688-e053-3705fe0a67e0 20
Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer, file 65498b7f-6545-4b8e-bb41-93b6e909eebb 19
Oncological care organisation during COVID-19 outbreak, file e2913fde-6615-f688-e053-3705fe0a67e0 18
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making, file 0cb99f9c-c7e4-46ec-b699-7ff650e15603 17
Expected medium- And long-term impact of the COVID-19 outbreak in oncology, file e2913fde-6617-f688-e053-3705fe0a67e0 17
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells, file 66e0dd45-7a3f-45f8-86e3-34b88af6390b 16
The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis, file e2913fda-0089-f688-e053-3705fe0a67e0 16
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial, file e2913fde-2a59-f688-e053-3705fe0a67e0 16
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: A retrospective exploratory analysis of the BALLET study, file e2913fde-2bf1-f688-e053-3705fe0a67e0 16
EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience, file e2913fde-34fc-f688-e053-3705fe0a67e0 16
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib, file ec59ed15-0f27-4103-a0d4-11c30f0bc1b2 16
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study, file 8d1dfe24-6b6f-4d7b-a36f-f1826edabf20 15
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach, file 9cc7febd-1639-4af5-a778-6804d083aa0a 15
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study, file ba166a05-c67b-4cfb-8337-deff0b217d0d 15
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial, file e2913fdb-7749-f688-e053-3705fe0a67e0 15
Lenvatinib for the treatment of renal cell carcinoma, file e2913fdd-555e-f688-e053-3705fe0a67e0 15
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study, file e2913fde-42b8-f688-e053-3705fe0a67e0 15
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study, file e2913fde-7f57-f688-e053-3705fe0a67e0 15
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry, file e2913fdf-85e4-f688-e053-3705fe0a67e0 15
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study, file 6c281395-7cac-4e76-a9f4-3908bdf1e75d 13
DNA repair deficiency as circulating biomarker in prostate cancer, file b492b744-06d9-4fb2-b858-91a436d89c4d 13
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report, file 2baf5848-1de7-4dc0-86a0-29a7269536f6 12
Totale 10.592
Categoria #
all - tutte 22.933
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.933


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019166 0 0 0 0 0 0 0 0 0 0 0 166
2019/20202.033 140 147 131 269 164 181 161 216 220 140 140 124
2020/20211.885 158 176 164 139 230 218 181 139 133 124 134 89
2021/20221.646 138 171 147 196 155 106 87 75 84 128 263 96
2022/20231.710 45 137 265 173 162 130 70 94 111 179 224 120
2023/20242.863 122 258 241 201 216 337 266 378 147 185 395 117
Totale 11.179